Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Accumulated Expenses for 6 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • Quarterly Accumulated Expenses rose 78.19% to $1.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Sep 2025, up 78.19% year-over-year, with the annual reading at $1.4 million for FY2024, 38.17% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $1.2 million at Inhibikase Therapeutics, up from $813017.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $3.6 million in Q1 2022, with the low at $459997.0 in Q4 2022.
  • Average Accumulated Expenses over 5 years is $1.4 million, with a median of $980161.0 recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 2388.81% in 2021, then plummeted 77.86% in 2022.
  • Over 5 years, Accumulated Expenses stood at $2.1 million in 2021, then tumbled by 77.86% to $459997.0 in 2022, then skyrocketed by 391.3% to $2.3 million in 2023, then tumbled by 38.17% to $1.4 million in 2024, then dropped by 16.7% to $1.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.2 million, $813017.0, and $948712.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.